The neurokinin 1 receptor: a potential new target for anti-platelet therapy?

Current Opinion in Pharmacology

Volumn 8, Issue 2, 2008, Pages 114-119

  Jones, Sarah ^a   Gibbins, Jonathan M ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; APREPITANT; CILOSTAZOL; CLOPIDOGREL; CYCLOOXYGENASE 1; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; G PROTEIN COUPLED RECEPTOR; LAMIFIBAN; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR AGONIST; PHOSPHODIESTERASE INHIBITOR; PURINERGIC P2Y12 RECEPTOR; SUBSTANCE P; TACHYKININ DERIVATIVE; TACHYKININ RECEPTOR ANTAGONIST; THIENOPYRIDINE DERIVATIVE; THROMBOXANE A2 RECEPTOR STIMULATING AGENT; TICLOPIDINE; TIROFIBAN; UNINDEXED DRUG; VON WILLEBRAND FACTOR;

ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; BLEEDING DISORDER; CARDIOVASCULAR DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DRUG BINDING SITE; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; INTERMITTENT CLAUDICATION; NONHUMAN; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REVIEW; SIGNAL TRANSDUCTION; STROKE; THROMBOCYTE AGGREGATION INHIBITION;

ANIMALS; BLOOD PLATELETS; DRUG DELIVERY SYSTEMS; HUMANS; PLATELET AGGREGATION INHIBITORS; RECEPTORS, NEUROKININ-1; TACHYKININS; THROMBOSIS;

EID: 40649103595     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.01.004     Document Type: Review

References (46)

1. Gibbins J.M. Platelet adhesion signalling and the regulation of thrombus formation. J Cell Sci 117 (2004) 3415-3425
2. Phillips D.R., Conley P.B., Sinha U., and Andre P. Therapeutic approaches in arterial thrombosis. J Thromb Haemost 3 (2005) 1577-1589
3. Meadows T.A., and Bhatt D.L. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 100 (2007) 1261-1275. An excellent review that focuses on the clinical aspects of currently available anti-platelet agents, in addition to highlighting some of the more promising therapies that are being developed for the prevention and treatment of cardiovascular disease.
4. Ruggeri Z.M. Platelets in atherothrombosis. Nat Med 8 (2002) 1227-1234
5. Jackson S.P. The growing complexity of platelet aggregation. Blood 109 (2007) 5087-5095
6. Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res 99 (2006) 1293-1304
7. Jackson S.P., and Schoenwaelder S.M. Antiplatelet therapy: in search of the 'magic bullet'. Nat Rev Drug Discov 2 (2003) 775-789
8. Shattil S.J., Kashiwagi H., and Pampori N. Integrin signaling: the platelet paradigm. Blood 91 (1998) 2645-2657
9. Shattil S.J., and Newman P.J. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood 104 (2004) 1606-1615
10. Bhatt D.L., and Topol E.J. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2 (2003) 15-28
11. Duffy B., and Bhatt D.L. Antiplatelet agents in patients undergoing percutaneous coronary intervention: how many and how much?. Am J Cardiovasc Drugs 5 (2005) 307-318
12. Patrono C., Garcia Rodriguez L.A., Landolfi R., and Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353 (2005) 2373-2383
13. Bertrand M., Rupprecht H., Urban P., and Gershlick A. Double-blind study of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102 (2000) 624-629
14. Scarborough R.M., Kleiman N.S., and Phillips D.R. Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use?. Circulation 100 (1999) 437-444
15. Moshfegh K., Redondo M., Julmy F., Wuillemin W.A., Gebauer M.U., Haeberli A., and Meyer B.J. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. J Am Coll Cardiol 36 (2000) 699-705
16. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., and Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
17. Andre P., Delaney S.M., LaRocca T., Vincent D., DeGuzman F., Jurek M., Koller B., Phillips D.R., and Conley P.B. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest 112 (2003) 398-406
18. Angelillo-Scherrer A., de Frutos P., Aparicio C., Melis E., Savi P., Lupu F., Arnout J., Dewerchin M., Hoylaerts M., Herbert J., et al. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med 7 (2001) 215-221
19. Zhu L., Bergmeier W., Wu J., Jiang H., Stalker T.J., Cieslak M., Fan R., Boumsell L., Kumanogoh A., Kikutani H., et al. Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injury. Proc Natl Acad Sci U S A 104 (2007) 1621-1626
20. Graham G.J., Stevens J.M., Page N.M., Grant A.D., Brain S.D., Lowry P.J., and Gibbins J.M. Tachykinins regulate the function of platelets. Blood 104 (2004) 1058-1065. In this paper, the authors demonstrate that SP acts as a platelet agonist stimulating a variety of functional effects including platelet shape change, secretion and aggregation. Using an NK1 blocking antibody, these effects were shown to be mediated through the NK1 receptor that is present on the platelet surface. Platelets were also shown to contain a SP-like peptide, which was released upon activation, suggesting that SP may be stored in platelets and released as a secondary platelet agonist.
21. Jones S, Tucker KL, Sage T, Kaiser WJ, Barrett NE, Lowry PJ, Zimmer A, Hunt SP, Emerson M, Gibbins JM: Peripheral tachykinins and the neurokinin receptor NK1 are required for platelet thrombus formation. Blood 2008, 111:605-612. Recently identified tachykinins, endokinins A and B, were shown to act as platelet agonists in a manner similar to that of SP. Inhibition of the platelet NK1 receptor using L733-060 markedly reduced in vitro thrombus formation on immobilised collagen under arterial flow conditions. Similar results were obtained from the blood of NK1-deficient and SP-deficient mice clearly implicating endogenous tachykinins and the platelet NK1 receptor in thrombogenesis. In vivo, inhibition of the NK1 receptor using L733-060 protects mice against collagen-induced thromboembolism, suggesting that targeting the NK1 receptor may produce therapeutic benefit.
22. Page N.M., Bell N.J., Gardiner S.M., Manyonda I.T., Brayley K.J., Strange P.G., and Lowry P.J. Characterization of the endokinins: human tachykinins with cardiovascular activity. Proc Natl Acad Sci U S A 100 (2003) 6245-6250. This study identifies the human TAC4 gene and the four mRNA transcripts, which it encodes. These transcripts give rise to four novel tachykinins, endokinins A, B, C and D. Competitive ligand-binding studies showed that the C-terminal decapeptide sequence shared by endokinins A and B (EKA/B) displayed similar affinity for the NK1 receptor as SP. In addition, EKA/B exhibited identical haemodynamic effects to SP when administered to rats.
23. Lecci A., and Maggi C.A. Peripheral tachykinin receptors as potential therapeutic targets in visceral diseases. Expert Opin Ther Targets 7 (2003) 343-362
24. Patacchini R., and Maggi C.A. Peripheral tachykinin receptors as targets for new drugs. Eur J Pharmacol 429 (2001) 13-21
25. Rameshwar P. Substance P: a regulatory neuropeptide for hematopoiesis and immune functions. Clin Immunol Immunopathol 85 (1997) 129-133
26. Zhang Y., Lu L., Furlonger C., Wu G.E., and Paige C.J. Hemokinin is a hematopoietic-specific tachykinin that regulates B lymphopoiesis. Nat Immunol 1 (2000) 392-397
27. Kurtz M.M., Wang R., Clements M.K., Cascieri M.A., Austin C.P., Cunningham B.R., Chicchi G.G., and Liu Q. Identification, localization and receptor characterization of novel mammalian substance P-like peptides. Gene 296 (2002) 205-212
28. Maggi C.A. The mammalian tachykinin receptors. Gen Pharmacol 26 (1995) 911-944
29. Khawaja A.M., and Rogers D.F. Tachykinins: receptor to effector. Int J Biochem Cell Biol 28 (1996) 721-738
30. Bellucci F., Carini F., Catalani C., Cucchi P., Lecci A., Meini S., Patacchini R., Quartara L., Ricci R., Tramontana M., et al. Pharmacological profile of the novel mammalian tachykinin, hemokinin 1. Br J Pharmacol 135 (2002) 266-274
31. Camarda V., Rizzi A., Calo G., Guerrini R., Salvadori S., and Regoli D. Pharmacological profile of hemokinin 1: a novel member of the tachykinin family. Life Sci 71 (2002) 363-370
32. Mousli M., Bronner C., Landry Y., Bockaert J., and Rouot B. Direct activation of GTP-binding regulatory proteins (G-proteins) by substance P and compound 48/80. FEBS Lett 259 (1990) 260-262
33. Mousli M., Bueb J.L., Bronner C., Rouot B., and Landry Y. G protein activation: a receptor-independent mode of action for cationic amphiphilic neuropeptides and venom peptides. Trends Pharmacol Sci 11 (1990) 358-362
34. Gudat F., Laubscher A., Otten U., and Pletscher A. Shape changes induced by biologically active peptides and nerve growth factor in blood platelets of rabbits. Br J Pharmacol 74 (1981) 533-538
35. 1 receptor is involved in the neurokinin-induced shape change of rabbit platelets. FEBS 312 (1992) 200-202
36. Gecse A., Kis B., Mezei Z., and Telegdy G. The effect of bradykinin and substance P on the arachidonate cascade of platelets. Immunopharmacology 33 (1996) 167-170
37. Kis B., Mezei Z., Gecse A., and Telegdy G. The effect of substance P on the arachidonate cascade of rat platelets. Acta Physiol Hung 85 (1997) 89-97
38. Gecse A., Kis B., Mezei Z., and Telegdy G. Effects of inflammatory neuropeptides on the arachidonate cascade of platelets. Int Arch Allergy Immunol 118 (1999) 166-170
39. Lecci A., Giuliani S., Tramontana M., Carini F., and Maggi C.A. Peripheral actions of tachykinins. Neuropeptides 34 (2000) 303-313
40. Duffy R.A. Potential therapeutic targets for neurokinin-1 receptor antagonists. Expert Opin Emerg Drugs 9 (2004) 9-21
41. Alvaro G., and Di Fabio R. Neurokinin 1 receptor antagonists - current prospects. Curr Opin Drug Discov Dev 10 (2007) 613-621. The authors discuss the wide therapeutic potential of NK1 receptor antagonists and the disappointment that they have brought because of their lack of effectiveness following initial encouraging results. The review reports on the large number of patents and scientific publications of new NK1 receptor antagonists issued in recent years, with emphasis on those from 2005 to 2006.
42. Palma C. Tachykinins and their receptors in human malignancies. Curr Drug Targets 7 (2006) 1043-1052
43. Liu K., Castillo M.D., Murthy R.G., Patel N., and Rameshwar P. Tachykinins and hematopoiesis. Clin Chim Acta 385 (2007) 28-34
44. Rost K., Fleischer F., and Nieber K. Neurokinin 1 receptor antagonists - between hope and disappointment. Med Monatsschr Pharm 29 (2006) 200-205
45. Patel L., and Lindley C. Aprepitant - a novel NK1-receptor antagonist. Expert Opin Pharmacother 4 (2003) 2279-2296
46. Lasseter K.C., Gambale J., Jin B., Bergman A., Constanzer M., Dru J., Han T.H., Majumdar A., Evans J.K., and Murphy M.G. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol 47 (2007) 834-840